However, the pooled sensitivity and specificity of the prostate cancer detection rates in the included 9 studies in this meta-analysis were 93% and 87%, respectively, and the results of the diagnosis of primary prostate cancer suggests that 68Ga-PSMA PET/CT can be used as one of the main screening methods for patients suspected with prostate cancer (with increased PSA levels, elderly patients with frequent urination, urgency, progressive urinary tract drainage and other clinical symptoms), and help determine the best treatment regimen. The gene discussed is FOLH1; the disease is Familial prostate cancer.